Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13494969 | 0.90 | POLB (0.32) | POLB | |
| SCHEMBL13185397 | 0.81 | POLB (0.37) | POLBCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL10037571 | 0.81 | POLB (0.37) | POLBCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2610530 | 0.80 | POLB (0.36) | POLBCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL12107536 | 0.79 | CYP1A2 (0.43) | POLBCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL13448309 | 0.77 | POLB (0.35) | POLBCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL327611 | 0.76 | SMN1; SMN2 (0.35) | POLBCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL10037551 | 0.76 | POLB (0.38) | POLBCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL10037527 | 0.74 | CPB2 (0.34) | POLBSLC1A2 | |
| SCHEMBL12505905 | 0.74 | HTT (0.35) | POLBHTTMEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178692-A1 | DOSAGE FORMS OF POLYMER-FACTOR VIII MOIETY CONJUGATES | NEKTAR THERAPEUTICS (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178692-A1 | DOSAGE FORMS OF POLYMER-FACTOR VIII MOIETY CONJUGATES | F8, F9, F13B | POLB 685/4885CYP1A2 653/4885CYP3A4 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.